Go Pro
→ Gold just passed our debt as the world's #1 asset (From Behind the Markets) (Ad)tc pixel Free NXGLW Stock Alerts

NEXGEL (NXGLW) Competitors

NEXGEL logo
$0.01 +0.00 (+4.44%)
As of 09/11/2026 11:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NXGLW vs. LUCYW, WOK, MDLN, ALC, and WST

Should you buy NEXGEL stock or one of its competitors? NEXGEL's main competitors and comparable companies include Innovative Eyewear (LUCYW), WORK Medical Technology Group (WOK), Medline (MDLN), Alcon (ALC), and West Pharmaceutical Services (WST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does NEXGEL compare to Innovative Eyewear?

NEXGEL (NASDAQ:NXGLW) and Innovative Eyewear (NASDAQ:LUCYW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
Innovative Eyewear N/A N/A N/A

In the previous week, NEXGEL and NEXGEL both had 1 articles in the media. NEXGEL's average media sentiment score of 1.87 beat Innovative Eyewear's score of 1.38 indicating that NEXGEL is being referred to more favorably in the media.

Company Overall Sentiment
NEXGEL Very Positive
Innovative Eyewear Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
Innovative Eyewear$3.41MN/AN/AN/AN/A

Summary

NEXGEL beats Innovative Eyewear on 2 of the 2 factors compared between the two stocks.

How does NEXGEL compare to WORK Medical Technology Group?

NEXGEL (NASDAQ:NXGLW) and WORK Medical Technology Group (NASDAQ:WOK) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, NEXGEL and NEXGEL both had 1 articles in the media. WORK Medical Technology Group's average media sentiment score of 1.89 beat NEXGEL's score of 1.87 indicating that WORK Medical Technology Group is being referred to more favorably in the news media.

Company Overall Sentiment
NEXGEL Very Positive
WORK Medical Technology Group Very Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NEXGEL has higher revenue and earnings than WORK Medical Technology Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
WORK Medical Technology Group$9.81MN/A-$1.07MN/AN/A

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
WORK Medical Technology Group N/A N/A N/A

Summary

WORK Medical Technology Group beats NEXGEL on 2 of the 3 factors compared between the two stocks.

How does NEXGEL compare to Medline?

NEXGEL (NASDAQ:NXGLW) and Medline (NASDAQ:MDLN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Medline has a consensus price target of $47.42, suggesting a potential upside of 45.78%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83

Medline has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
Medline$28.43B1.50$1.16B$0.7941.18

In the previous week, Medline had 11 more articles in the media than NEXGEL. MarketBeat recorded 12 mentions for Medline and 1 mentions for NEXGEL. NEXGEL's average media sentiment score of 1.87 beat Medline's score of 1.17 indicating that NEXGEL is being referred to more favorably in the media.

Company Overall Sentiment
NEXGEL Very Positive
Medline Positive

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
Medline N/A N/A N/A

Summary

Medline beats NEXGEL on 6 of the 7 factors compared between the two stocks.

How does NEXGEL compare to Alcon?

Alcon (NYSE:ALC) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Alcon has a net margin of 5.92% compared to NEXGEL's net margin of 0.00%. Alcon's return on equity of 7.29% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
Alcon5.92% 7.29% 5.09%
NEXGEL N/A N/A N/A

Alcon has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alcon$10.40B3.14$980M$1.3150.43
NEXGEL$12.07MN/AN/AN/AN/A

53.9% of Alcon shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alcon currently has a consensus target price of $84.96, indicating a potential upside of 28.60%. Given Alcon's stronger consensus rating and higher possible upside, equities analysts clearly believe Alcon is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alcon
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.61
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Alcon had 1 more articles in the media than NEXGEL. MarketBeat recorded 2 mentions for Alcon and 1 mentions for NEXGEL. NEXGEL's average media sentiment score of 1.87 beat Alcon's score of 0.17 indicating that NEXGEL is being referred to more favorably in the news media.

Company Overall Sentiment
Alcon Neutral
NEXGEL Very Positive

Summary

Alcon beats NEXGEL on 10 of the 11 factors compared between the two stocks.

How does NEXGEL compare to West Pharmaceutical Services?

NEXGEL (NASDAQ:NXGLW) and West Pharmaceutical Services (NYSE:WST) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

West Pharmaceutical Services has a consensus price target of $373.85, suggesting a potential upside of 8.21%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts clearly believe West Pharmaceutical Services is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
West Pharmaceutical Services
0 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.87

In the previous week, West Pharmaceutical Services had 17 more articles in the media than NEXGEL. MarketBeat recorded 18 mentions for West Pharmaceutical Services and 1 mentions for NEXGEL. NEXGEL's average media sentiment score of 1.87 beat West Pharmaceutical Services' score of 1.06 indicating that NEXGEL is being referred to more favorably in the media.

Company Overall Sentiment
NEXGEL Very Positive
West Pharmaceutical Services Positive

West Pharmaceutical Services has a net margin of 16.98% compared to NEXGEL's net margin of 0.00%. West Pharmaceutical Services' return on equity of 20.11% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
West Pharmaceutical Services 16.98%20.11%14.83%

West Pharmaceutical Services has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
West Pharmaceutical Services$3.07B7.91$493.70M$7.8144.24

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

West Pharmaceutical Services beats NEXGEL on 11 of the 12 factors compared between the two stocks.

Get NEXGEL News Delivered to You Automatically

Sign up to receive the latest news and ratings for NXGLW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXGLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NXGLW vs. The Competition

Export
MetricNEXGELHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$5.40B$7.15B$12.84B
Dividend YieldN/A1.80%2.57%11.71%
P/E RatioN/A25.09275.2525.35
Price / SalesN/A71.67637.6390.72
Price / CashN/A33.0328.4234.96
Price / BookN/A5.9710.416.21
Net IncomeN/A$150.75M$3.50B$358.54M
7 Day PerformanceN/A-2.71%-3.29%-2.39%
1 Month PerformanceN/A-3.32%-0.84%-3.39%
1 Year PerformanceN/A9.47%23.56%8.81%

NEXGEL Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXGLW
NEXGEL
N/A$0.01
+4.4%		N/A-95.4%$0.00$12.07MN/A10
LUCYW
Innovative Eyewear
N/A$0.04
-9.2%		N/A-49.9%$0.00$3.41MN/A9
WOK
WORK Medical Technology Group
1.3663 of 5 stars		$1.98
-1.9%		N/A-100.0%$0.00$9.81MN/A226
MDLN
Medline
3.6286 of 5 stars		$32.75
-3.8%		$47.42
+44.8%		N/A$43.07B$28.43B41.4745,000
ALC
Alcon
3.2898 of 5 stars		$66.92
-2.2%		$84.96
+27.0%		-15.6%$33.10B$10.40B51.0925,942

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NXGLW) was last updated on 9/14/2026 by MarketBeat.com Staff.
From Our Partners
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
Print this before your next trade
Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...
Profits Run | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
This little-known gold fund distributes cash every Friday
Gold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...
Investors Alley | Sponsoredtc pixel